GlassScriptPhysician profile
Steven A Salinger
NPI 1144325069
$3,695.37
in general payments reported to CMS, 2019-2025
40 companies · $22.28 in 2025
The $22.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $1,226 · 2021: $214 · 2022: $83.49 · 2023: $338 · 2024: $302 · 2025: $22.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $541.80 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $458.20 | 2019-2023 | Prolia, Evenity |
| Pfizer INC. | $449.25 | 2019-2024 | |
| Allergan, INC. | $413.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $230.68 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $166.46 | 2019-2021 | |
| Abbvie INC. | $161.77 | 2020-2023 | Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $122.85 | 2019-2020 | |
| Novo Nordisk INC | $115.57 | 2019-2020 | |
| Astellas Pharma US INC | $112.86 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $97.48 | 2019 | |
| Exact Sciences Corporation | $89.88 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.36 | 2022-2023 | |
| Lilly USA, LLC | $54.33 | 2019-2020 | |
| Antares Pharma, INC. | $43.30 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Salinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.